

## INTERLEUKIN 22 POLYMORPHISMS AND PAPILLARY THYROID CANCER

Eun, Young Gyu<sup>1</sup>; Park, Gi Cheol<sup>2</sup>.

<sup>1</sup>Kyung Hee University Medical Center, Seoul, Republic of Korea; <sup>2</sup>Sungkyunkwan university school of medicine, Samsung Changwon Hospital, Changwon-si, Republic of Korea.

**Background/Purpose:** To analyze the relationships between single nucleotide polymorphisms (SNPs) in IL22, IL22RA1 and papillary thyroid cancer (PTC).

**Methods:** *Study design:* Case-control study. *Setting:* Tertiary academic hospital.

*Subjects and Methods:* Study enrolled experimental group of 94 PTC patients and 213 controls. PTC patients were grouped and compared for clinical PTC parameters. One promoter SNP of IL22, -429C/T (rs2227485), and one SNP of IL22RA1, Arg518Gly (rs3795299) were analyzed using direct sequencing. Genetic data were analyzed using HelixTree, SNPAnalyzer Pro, SNPStats, and Haploview.

**Results:** A SNP in IL22 (rs2227485) was significantly associated (codominant model [C/C vs. T/T], OR = 2.39, 95% CI = 1.21-4.71,  $P = 0.012$ ; dominant model, OR = 1.89, 95% CI = 1.08-3.31,  $P = 0.022$ ) with PTC. The allele T frequency of rs2227485 in IL22 was also associated with PTC (OR = 1.59, 95% CI = 1.13-2.25,  $P = 0.009$ ). According to clinical parameters, rs2227485 of IL22 was associated with number of cancers (dominant model, OR = 3.03, 95% CI = 1.02-9.01,  $P = 0.035$ ). By haplotype analysis, TG was associated with PTC (codominant model, OR = 1.52, 95% CI = 1.07-2.16,  $P = 0.019$ ; dominant model, OR = 1.91, 95% CI = 1.13-3.24,  $P = 0.015$ ). Genotype and allele analysis of rs3795299 in IL22RA1 showed no significant differences between PTC patients and controls.

**Discussion & Conclusion:** The rs2227485 SNP in IL22 might be associated with the risk and the multifocality of PTC.